* Adicet Bio Inc ACET.OQ ACET.O is expected to show a
fall in
quarterly revenue when it reports results on May 10
(estimated).
*
* Refinitiv's mean analyst estimate for Adicet Bio Inc is
for a
loss of 69 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 10 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Adicet Bio
Inc is
$27.5, above its last closing price of $6.66.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Dec. 31 2022 0.29 -0.28 -0.72 Missed -158.1
Sep. 30 2022 -0.55 -0.53 -0.53 Met -0.6
Jun. 30 2022 -0.44 -0.45 -0.56 Missed -23.1
Mar. 31 2022 -0.24 -0.18 0.10 Beat 154.9
Dec. -0.25 -0.42 -0.47 Missed -11.6
31 2021
Sep. 30 2021 -0.44 -0.44 -0.44 Met 0
Jun. 30 2021 -0.53 -0.53 -0.34 Beat 35.8
Mar. 31 2021 -0.43 -0.49 -0.82 Missed -67.9
This summary was machine generated May 9 at 02:04 GMT. All
figures in US dollars unless otherwise stated